Heart failure drug combo may improve valve function
NCT ID NCT07379788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in 180 heart failure patients compared the effects of taking Entresto alone versus Entresto plus a second drug (empagliflozin) on mitral valve function and heart pumping ability. Participants had heart failure with reduced ejection fraction and some degree of functional mitral regurgitation. The study measured changes in heart structure and function using echocardiography.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacubitril/Valsartan (Entresto) and Empagliflozin
What this could lead to
If successful, this could show that adding an SGLT2 inhibitor to standard ARNI therapy improves heart valve function and heart pumping ability in people with heart failure.
What could go wrong
This is a small, completed study with no phase designation, so results may not be definitive or widely applicable. The outcomes are imaging-based measures, not long-term clinical benefits like survival or hospitalizations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Madinah Cardiac Center
Madinah, Saudi Arabia